What is the primary purpose of these offerings announced by Vertex Pharmaceuticals?

The primary purpose of these offerings is to raise capital for Vertex Pharmaceuticals. The exact use of the funds is not detailed in this 8-K, but typically such capital raises are for general corporate purposes, research and development, clinical trials, or potential acquisitions.

How much capital is Vertex Pharmaceuticals aiming to raise through these offerings?

Vertex Pharmaceuticals is aiming to raise approximately $102.84 million from the common stock offering (6,000,000 shares * $17.14/share) and $250 million from the notes offering, for a total of approximately $352.84 million, before considering any over-allotment options.

What are the key terms of the convertible senior subordinated notes being offered?

The notes are 4.75% convertible senior subordinated notes due 2013. They are being offered in an aggregate principal amount of $250,000,000. The specific conversion features and other indenture details would be found in the prospectus referenced in the filing, but not elaborated in this 8-K.

Who are the underwriters involved in these offerings?

The underwriters for both the common stock and the notes offerings include Merrill, Lynch, Pierce, Fenner & Smith Incorporated, Goldman, Sachs & Co., Morgan Stanley & Co. Incorporated, and J.P. Morgan Securities Inc.

VRTX 8-K: Material Agreements

Summary

Vertex Pharmaceuticals Incorporated (VRTX) announced on February 12, 2008, that it entered into two material agreements: a common stock offering and a convertible senior subordinated notes offering. These transactions were designed to raise capital for the company's ongoing operations and potential future development. The company is selling 6,000,000 shares of common stock at an offering price of $17.14 per share. Additionally, Vertex is offering $250,000,000 in aggregate principal amount of 4.75% convertible senior subordinated notes due 2013. The underwriters for both offerings have been granted options to purchase additional shares and notes to cover over-allotments, indicating strong demand or a strategy to maximize capital raised.

Key Highlights

1Vertex Pharmaceuticals entered into an underwriting agreement for the sale of 6,000,000 shares of common stock at $17.14 per share.
2The company is also selling $250,000,000 in 4.75% convertible senior subordinated notes due 2013.
3Underwriters have an option to purchase up to an additional 900,000 shares of common stock to cover over-allotments.
4Underwriters also have an option to purchase up to an additional $37,500,000 in principal amount of notes to cover over-allotments.
5These offerings are intended to raise capital for the company.
6The underwriting agreements were dated February 12, 2008.
7The filings include the underwriting agreements as exhibits.

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Material Agreement (Feb 14, 2008)

Summary

Key Highlights

Frequently Asked Questions